Search Results - "Thul, Joan"

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Su1866 RETROSPECTIVE SUBGROUP ANALYSIS OF RBX2660 ADMINISTERED BY COLONOSCOPY UNDER ENFORCEMENT DISCRETION FOR THE PREVENTION OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION

    Su1866 RETROSPECTIVE SUBGROUP ANALYSIS OF RBX2660 ADMINISTERED BY COLONOSCOPY UNDER ENFORCEMENT DISCRETION FOR THE PREVENTION OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION by Knapple, Whitfield L., Yoho, David S., Sheh, Alexander, Thul, Joan, Feuerstadt, Paul

    Published in Gastroenterology (New York, N.Y. 1943) (01-05-2023)
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    S195 Efficacy and Safety of Fecal Microbiota, Live-jslm in Older Participants With Recurrent Clostridioides difficile Infection and Underlying Comorbidities: An Ad Hoc Analysis of an Open-Label, Phase 3 Study

    S195 Efficacy and Safety of Fecal Microbiota, Live-jslm in Older Participants With Recurrent Clostridioides difficile Infection and Underlying Comorbidities: An Ad Hoc Analysis of an Open-Label, Phase 3 Study by Warren, Cirle A., Tillotson, Glenn, Guthmueller, Beth, Thul, Joan, Feuerstadt, Paul, Gonzales-Luna, Anne J., Carlson, Travis J.

    Published in The American journal of gastroenterology (01-10-2023)
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA ® ) administered by colonoscopy under enforcement discretion for the prevention of recurrent Clostridioides difficile infection

    Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA ® ) administered by colonoscopy under enforcement discretion for the prevention of recurrent Clostridioides difficile infection by Knapple, Whitfield L, Yoho, David S, Sheh, Alexander, Thul, Joan, Feuerstadt, Paul

    Published in Therapeutic advances in gastroenterology (01-01-2024)
    “…Fecal microbiota, live-jslm (RBL; REBYOTA ), is the first Food and Drug Administration (FDA)-approved, single-dose, rectally administered, microbiota-based…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  4. 4
    706. An Ad Hoc Subgroup Analysis of a Phase 3, Open-Label Study Indicates Efficacy and Safety of Fecal Microbiota, Live-jslm in Participants With Recurrent Clostridioides difficile Infection and Renal Impairment

    706. An Ad Hoc Subgroup Analysis of a Phase 3, Open-Label Study Indicates Efficacy and Safety of Fecal Microbiota, Live-jslm in Participants With Recurrent Clostridioides difficile Infection and Renal Impairment by Fischer, Monika, Thul, Joan, Guthmueller, Beth, Sandrock, Christian, Van Hise, Nicholas, Tillotson, Glenn S

    Published in Open forum infectious diseases (27-11-2023)
    “…Abstract Background Patients with renal comorbidity are at risk of severe Clostridioides difficile infection (CDI) and recurrence. Fecal microbiota, live-jslm…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  5. 5
    Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA) administered by colonoscopy under enforcement discretion for the prevention of recurrent infection

    Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA) administered by colonoscopy under enforcement discretion for the prevention of recurrent infection by Whitfield L. Knapple, David S. Yoho, Alexander Sheh, Joan Thul, Paul Feuerstadt

    Published in Therapeutic advances in gastroenterology (01-03-2024)
    “…Background: Fecal microbiota, live-jslm (RBL; REBYOTA ® ), is the first Food and Drug Administration (FDA)-approved, single-dose, rectally administered,…”
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: